News
DARE
3.340
+0.30%
0.010
Daré Bioscience Announces New Corporate Presentation
TipRanks · 1d ago
Weekly Report: what happened at DARE last week (0106-0110)?
Weekly Report · 2d ago
Weekly Report: what happened at DARE last week (1230-0103)?
Weekly Report · 01/06 10:10
Weekly Report: what happened at DARE last week (1223-1227)?
Weekly Report · 12/30/2024 10:07
Weekly Report: what happened at DARE last week (1216-1220)?
Weekly Report · 12/23/2024 10:10
U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Benzinga · 12/18/2024 16:11
Optimistic Buy Rating for Daré Bioscience Driven by Strategic Progress and Financial Position
TipRanks · 12/17/2024 11:15
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder
Barchart · 12/16/2024 17:24
Dare Bioscience announces Phase 3 plans for sildenafil cream in FSAD
TipRanks · 12/16/2024 13:35
Daré Bioscience Advances Sildenafil Cream to Phase 3 Study
TipRanks · 12/16/2024 13:27
Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD
Benzinga · 12/16/2024 13:17
DARÉ BIOSCIENCE ANNOUNCES PHASE 3 PLANS FOR SILDENAFIL CREAM, 3.6%, IN THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER (FSAD)
Reuters · 12/16/2024 13:01
Weekly Report: what happened at DARE last week (1209-1213)?
Weekly Report · 12/16/2024 10:11
Dare Bioscience announces publication in Sexual Medicine on RESPOND study
TipRanks · 12/10/2024 13:10
Weekly Report: what happened at DARE last week (1202-1206)?
Weekly Report · 12/09/2024 10:10
Dare Bioscience received payment of $2.5M under grant agreement
TipRanks · 12/04/2024 13:12
DARÉ BIOSCIENCE ANNOUNCES $2.5 MILLION GRANT FUNDING INSTALLMENT TO SUPPORT FURTHER DEVELOPMENT OF NOVEL CONTRACEPTIVE TECHNOLOGY DARE-LARC1
Reuters · 12/04/2024 13:07
Press Release: Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dow Jones · 12/04/2024 13:00
Press Release: Daré Bioscience Announces $2.5 -2-
Dow Jones · 12/04/2024 13:00
Weekly Report: what happened at DARE last week (1125-1129)?
Weekly Report · 12/02/2024 10:10
More
Webull provides a variety of real-time DARE stock news. You can receive the latest news about Dare Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.